Discover How Patient-Specific Insulin Dosing Transforms Glycemic Outcomes

What We’ll Cover

• How Estimated Residual Extracellular Insulin (EREI) works and why it produces different outcomes than population-level insulin dosing models
• Published comparison data across severe hypoglycemia, overall hypoglycemia, and time-to-target metrics
• What a joint clinical and IT evaluation process looks like, and how pharmacy, endocrinology, and informatics teams typically align on criteria
• Integration with your EHR and the data your team needs for eCQM reporting

Pharmacy and therapeutics committees reviewing insulin dosing options need defensible evidence. This 30-minute conversation can give your team the clinical and technical answers to bring to that review.

Proven and Clinically Validated

EndoTool, Glooko’s FDA-cleared patient-specific insulin dosing system, has demonstrated 0.05% severe hypoglycemia versus 3.9% with a competitor system in peer-reviewed studies, with consistent results for renal-compromised patients.